HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[New drugs in the treatment of childhood epilepsy: vigabatrin (study of 61 subjects)].

Abstract
This study was conducted to determine the efficacy of vigabatrin in children with epilepsy. Sixty-one children with various types of severe epilepsy were studied. In 12 children vigabatrin was introduced as monotherapy, while in 49 it was added to other antiepileptic drugs. Following the introduction of vigabatrin, 17 patients became seizure free, and 19 responded with a greater than 50% reduction in seizure frequency. The following types of epilepsy responded favorably to treatment (in order of decreasing efficacy): West syndrome, especially if secondary to Tuberous Sclerosis; cryptogenic and symptomatic partial epilepsy; Lennox-Gastaut syndrome, and other symptomatic generalized epilepsy. Optimal responses were found with vigabatrin doses of 30 to 50 mg/kg/day. Forty-one responders continued on vigabatrin, with generally good efficacy. Vigabatrin tolerability was good; in only 6 children was treatment discontinued because of side-effects such as somnolence, irritability, weight gain, and cutaneous rash. This study shows that vigabatrin is effective in the treatment of refractory epilepsy, especially in West syndrome secondary to Tuberous Sclerosis, partial epilepsy, and Lennox-Gastaut syndrome. Further studies are needed to analyze the increased frequency of seizures and the appearance of new seizure types associated with vigabatrin treatment.
AuthorsU Raucci, A Spalice, L A Basile, C Guardalà, L Nasta, S Terenzi, P Iannetti
JournalLa Pediatria medica e chirurgica : Medical and surgical pediatrics (Pediatr Med Chir) 1994 Nov-Dec Vol. 16 Issue 6 Pg. 575-8 ISSN: 0391-5387 [Print] Italy
Vernacular TitleNuovi farmaci nella terapia dell'epilessia dell'infanzia: vigabatrin (studio di 61 soggetti).
PMID7708543 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Anticonvulsants
  • gamma-Aminobutyric Acid
  • 4-Aminobutyrate Transaminase
  • Vigabatrin
Topics
  • 4-Aminobutyrate Transaminase (antagonists & inhibitors)
  • Adolescent
  • Age Factors
  • Anticonvulsants (administration & dosage, adverse effects, therapeutic use)
  • Child
  • Child, Preschool
  • Drug Tolerance
  • Epilepsies, Myoclonic (drug therapy)
  • Epilepsy (drug therapy, etiology)
  • Epilepsy, Generalized (drug therapy)
  • Female
  • Humans
  • Infant
  • Male
  • Time Factors
  • Tuberous Sclerosis (complications)
  • Vigabatrin
  • gamma-Aminobutyric Acid (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: